International Journal of
ADVANCED RESEARCH & INNOVATIONS

Volume 14, Issue-12
December, 2024, P02
ISSN: 2319-9253

CROSS-MODAL ARTIFICIAL INTELLIGENCE FOR PRECISION ONCOLOGY: BRIDGING RADIOLOGY, HISTOPATHOLOGY, GENOMICS, AND CLINICAL RECORDS

[#1] **Dr. Ritesh Kulkarni**, Professor, Department of Medical Oncology,
Mahatma Gandhi Medical College and Hospital, Jaipur, India
Riteshkulkarni81@gmail.com

Abstract: Precision oncology has entered an era in which artificial intelligence (AI) is no longer confined to individual diagnostic tasks but instead functions as an integrative computational framework capable of unifying heterogeneous biomedical information across the entire cancer care continuum. Conventional machine learning approaches have achieved remarkable success in isolated domains such as radiology, digital pathology, genomics, or electronic health records; however, their modality-specific design frequently limits comprehensive understanding of tumor biology and clinical decision-making. Recent advances in cross-modal artificial intelligence, including foundation models, multimodal transformers, graph neural networks, self-supervised learning, and generative AI, have enabled seamless integration of radiological imaging, histopathology, genomics, transcriptomics, proteomics, metabolomics, epigenomics, laboratory biomarkers, electronic health records, wearable technologies, and longitudinal clinical outcomes into unified patient-centered computational representations. These intelligent systems facilitate molecular characterization, biomarker discovery, prognostic prediction, therapeutic optimization, immunotherapy selection, digital twin simulation, adaptive disease monitoring, and clinical decision support while accelerating precision medicine. Emerging technologies such as multimodal large language models, federated learning, reinforcement learning, retrieval-augmented generation, explainable artificial intelligence, and agentic AI further strengthen cross-modal computational oncology by enabling collaborative, privacy-preserving, and continuously adaptive learning across diverse healthcare environments. Despite extraordinary technological progress, important scientific, technical, ethical, and regulatory challenges remain regarding multimodal data harmonization, computational scalability, interpretability, interoperability, cybersecurity, clinical validation, and equitable implementation. This review provides a comprehensive overview of cross-modal artificial intelligence for precision oncology, emphasizing integration of radiology, histopathology, genomics, and clinical records as the foundation for future intelligent cancer medicine.[1]

Keywords: *Cross-modal artificial intelligence, Precision oncology, Foundation models, Radiology, Histopathology, Genomics, Clinical records, Multimodal learning, Computational oncology, Clinical decision support.*

1. Introduction

Cancer is a biologically heterogeneous disease characterized by dynamic interactions among genomic alterations, epigenetic regulation, transcriptional activity, protein signaling, immune responses, metabolic adaptation, tissue architecture, environmental influences, and host physiology. These interconnected biological processes evolve continuously throughout diagnosis, treatment, recurrence, metastasis, and survivorship, making precision oncology increasingly dependent upon comprehensive computational integration of diverse biomedical information.[2]

Modern oncology routinely generates enormous quantities of heterogeneous data through radiological imaging, digital histopathology, genomic sequencing, transcriptomics, proteomics, metabolomics, laboratory investigations, wearable physiological monitoring, electronic health

International Journal of
ADVANCED RESEARCH & INNOVATIONS
Volume 14, Issue-12
December, 2024, P02
ISSN: 2319-9253

records, physician documentation, and patient-reported outcomes. Although each modality provides valuable biological insight, isolated interpretation frequently fails to capture the systems-level interactions governing tumor evolution and therapeutic response.[3]
Artificial intelligence has emerged as a transformative computational technology capable of integrating these diverse biomedical modalities into unified patient-specific representations. Cross-modal AI extends beyond traditional multimodal learning by establishing computational relationships among complementary diagnostic domains while enabling holistic clinical reasoning across the cancer care continuum.[4]
The convergence of cross-modal artificial intelligence, foundation models, precision medicine, and clinical oncology therefore represents a transformative paradigm for intelligent cancer diagnosis, prognostic prediction, therapeutic optimization, and personalized healthcare.[5]

2. Evolution of Cross-Modal Artificial Intelligence

Early artificial intelligence applications in oncology primarily focused on modality-specific algorithms developed independently for radiological image interpretation, computational pathology, genomic analysis, or electronic health record mining. Although these systems demonstrated considerable success, they frequently lacked the capacity to integrate complementary biomedical information into coherent clinical reasoning frameworks.[6]
Deep learning subsequently enabled automated representation learning from high-dimensional biomedical datasets without requiring handcrafted feature engineering. Transformer architectures further revolutionized computational medicine by enabling efficient modeling of long-range contextual relationships across heterogeneous data modalities.
Foundation AI models have now extended these capabilities through large-scale self-supervised learning capable of acquiring generalized biomedical knowledge transferable across multiple oncology applications. Cross-modal learning further aligns imaging, pathology, molecular biology, and clinical information within shared computational embedding spaces, substantially improving biological understanding and clinical performance.
Today, cross-modal AI represents one of the most advanced computational paradigms supporting intelligent precision oncology.[7]

3. Principles of Cross-Modal Artificial Intelligence

Cross-modal artificial intelligence differs fundamentally from conventional machine learning because it simultaneously learns relationships among multiple complementary biomedical modalities rather than analyzing individual datasets independently. Foundation AI models generate generalized biomedical representations that integrate radiological imaging, digital histopathology, genomics, transcriptomics, proteomics, metabolomics, laboratory biomarkers, wearable physiological monitoring, physician documentation, and longitudinal clinical trajectories into unified computational frameworks.[8]
Self-supervised learning enables discovery of latent biological relationships without extensive manual annotation, while multimodal transformer architectures align heterogeneous biomedical modalities within shared computational embedding spaces. Graph neural networks further model interactions among genes, proteins, signaling pathways, imaging phenotypes, tissue architecture, immune populations, therapeutic targets, physiological variables, and clinical outcomes.
These integrated computational principles enable cross-modal AI to perform systems-level reasoning regarding cancer biology while supporting adaptive precision oncology throughout the patient journey.[9]

4. Computational Architecture

Modern cross-modal AI platforms consist of interconnected computational layers responsible for multimodal biomedical data acquisition, preprocessing, representation learning, cross-modal fusion, predictive analytics, adaptive

Paper Available at: www.ijarai.com
DOI : https://doi.org/10.65713/ijaraiv14i1202

International Journal of ADVANCED RESEARCH & INNOVATIONS
Volume 14, Issue-12
December, 2024, P02
ISSN: 2319-9253

learning, and intelligent clinical decision support.[10]
The acquisition layer continuously incorporates radiological imaging, digital pathology, genomic sequencing, transcriptomics, proteomics, metabolomics, epigenomics, spatial biology, laboratory investigations, liquid biopsy, wearable physiological monitoring, medication history, physician documentation, patient-reported outcomes, and longitudinal electronic health records. Advanced preprocessing pipelines normalize imaging studies, harmonize molecular datasets, encode unstructured clinical narratives using natural language processing, and synchronize temporal patient information.
Foundation AI models subsequently generate generalized multimodal embeddings representing molecular biology, tissue architecture, anatomical imaging, physiological function, and longitudinal clinical trajectories. Cross-modal fusion modules integrate these representations into comprehensive patient-centered computational frameworks supporting diagnosis, prognostic prediction, therapeutic planning, digital twin simulation, and intelligent clinical reasoning.[11]

5. Cross-Modal Integration of Radiology and Histopathology

Radiological imaging and digital histopathology provide complementary perspectives of tumor biology across macroscopic and microscopic scales. Radiology characterizes anatomical morphology, vascularity, metabolism, and organ-level disease distribution, whereas histopathology provides microscopic assessment of cellular morphology, tissue architecture, immune infiltration, angiogenesis, fibrosis, necrosis, and stromal remodeling.[12]
Foundation AI models integrate these complementary imaging modalities using transformer architectures and graph neural networks capable of identifying latent relationships between imaging phenotypes and microscopic tissue characteristics. Artificial intelligence learns cross-scale biological representations that improve tumor classification, molecular characterization, prognostic prediction, biomarker discovery, and therapeutic planning.
This integration substantially strengthens computational pathology, radiology, and precision oncology by bridging anatomical and cellular information within unified computational frameworks.[13]

6. Integrating Genomics and Multi-Omics

Comprehensive precision oncology increasingly depends upon integration of genomics, transcriptomics, proteomics, metabolomics, epigenomics, immunomics, microbiomics, spatial biology, and single-cell sequencing into unified molecular representations of cancer biology.[14]
Foundation AI models utilize multimodal transformers, graph neural networks, biological knowledge graphs, and self-supervised learning to identify complex relationships among genes, proteins, metabolites, signaling pathways, immune responses, imaging phenotypes, and histopathological characteristics that remain difficult to detect through isolated analytical methods.
These integrated molecular representations substantially improve biomarker discovery, molecular subtype classification, therapeutic response prediction, systems biology research, and individualized precision medicine while strengthening cross-modal computational oncology.[15]

7. Clinical Records as Longitudinal Intelligence

Electronic health records provide longitudinal clinical context that complements imaging and molecular diagnostics by documenting diagnoses, laboratory investigations, medications, physician observations, procedures, treatment responses, adverse events, hospitalizations, and survivorship trajectories. Natural language processing and temporal transformer architectures enable foundation AI models to integrate structured and unstructured clinical information into comprehensive patient-centered computational representations.[16]
Artificial intelligence continuously updates these clinical embeddings as new information becomes available, enabling adaptive prediction of disease progression, therapeutic response, recurrence, toxicity, hospitalization, and survival while

Paper Available at: www.ijarai.com
DOI : https://doi.org/10.65713/ijaraiv14i1202

strengthening evidence-based clinical reasoning throughout the oncology care continuum.[17]

8. Foundation AI Models for Cross-Modal Biomarker Discovery

Cross-modal artificial intelligence substantially enhances biomarker discovery by simultaneously analyzing radiological imaging, digital histopathology, genomics, transcriptomics, proteomics, metabolomics, laboratory biomarkers, and longitudinal clinical outcomes. Foundation AI models identify latent biological signatures spanning imaging phenotypes, tissue architecture, molecular alterations, immune activation, metabolic adaptation, therapeutic sensitivity, treatment resistance, recurrence, and survival.[18]

These integrated computational biomarkers improve diagnostic classification, prognostic assessment, companion diagnostics, immunotherapy selection, therapeutic monitoring, and personalized treatment planning while accelerating translation of computational discoveries into routine precision oncology.[19]

9. Cross-Modal Therapeutic Decision-Making

One of the most important clinical applications of cross-modal artificial intelligence is individualized therapeutic decision-making through comprehensive integration of imaging, pathology, genomics, laboratory medicine, medication history, and longitudinal clinical trajectories. Foundation AI models simultaneously analyze heterogeneous biomedical information to predict responsiveness to chemotherapy, targeted therapy, endocrine therapy, immunotherapy, radiation therapy, surgery, and multimodal treatment combinations while estimating toxicity, recurrence probability, progression-free survival, and overall survival.[20]

10. Digital Twins and Virtual Cross-Modal Patient Models

Digital twin technology extends cross-modal artificial intelligence by creating continuously evolving virtual representations of individual cancer patients that integrate radiological imaging, digital histopathology, genomics, transcriptomics, proteomics, metabolomics, laboratory biomarkers, wearable physiological monitoring, medication history, and longitudinal clinical records into unified computational ecosystems.[21]

Foundation AI models continuously synchronize these virtual patients with newly acquired biomedical information, enabling simulation of tumor evolution, therapeutic response, treatment-related toxicity, recurrence, metastatic dissemination, immune adaptation, and long-term survival under multiple therapeutic scenarios. Cross-modal digital twins therefore provide clinicians with an opportunity to evaluate alternative treatment strategies before implementation in routine clinical practice.

By integrating anatomical imaging, microscopic pathology, molecular biology, and longitudinal clinical intelligence, digital twin ecosystems transform predictive oncology from static forecasting toward continuously adaptive virtual precision medicine.

11. Intelligent Clinical Decision Support

Cross-modal artificial intelligence provides the computational foundation for next-generation clinical decision-support systems capable of integrating heterogeneous biomedical information into comprehensive patient-centered recommendations. Radiological imaging, digital pathology, molecular diagnostics, laboratory investigations, wearable physiological monitoring, medication history, physician documentation, patient-reported outcomes, and evidence-based clinical guidelines are synthesized into unified computational environments supporting multidisciplinary oncology practice.[22]

Interactive clinical dashboards generate individualized diagnostic summaries, multimodal biomarker analyses, molecular interpretations, digital twin simulations, therapeutic recommendations, toxicity estimates, recurrence probabilities, and survival forecasts while facilitating collaboration among oncologists, radiologists, pathologists, surgeons, radiation oncologists, molecular biologists, pharmacists, nurses, genetic counselors, and computational scientists.

These intelligent systems improve workflow efficiency, reduce information fragmentation, strengthen multidisciplinary communication, and promote evidence-based personalized cancer management across the entire oncology care continuum.

12. Continuous Learning and Adaptive Clinical Intelligence

Unlike conventional artificial intelligence systems that remain static after deployment, cross-modal foundation models continuously evolve through dynamic integration of newly acquired biomedical information. Artificial intelligence incorporates serial imaging examinations, computational pathology, circulating tumor DNA, laboratory biomarkers, wearable physiological monitoring, medication adherence, patient-reported outcomes, and real-world clinical evidence into adaptive computational frameworks capable of continuously refining predictive accuracy.[23]

Continual learning algorithms update computational models without catastrophic forgetting of previously acquired knowledge, while reinforcement learning optimizes therapeutic recommendations through iterative evaluation of treatment outcomes. Consequently, cross-modal artificial intelligence remains synchronized with evolving tumor biology, emerging scientific discoveries, changing clinical guidelines, and individual patient trajectories.

This adaptive computational paradigm transforms oncology into a continuously learning healthcare ecosystem capable of supporting real-time precision medicine.

13. Federated Cross-Modal Intelligence

The development of highly generalizable cross-modal foundation models requires access to diverse biomedical datasets representing multiple healthcare systems, imaging platforms, molecular technologies, and patient populations. Federated learning enables collaborative development of cross-modal artificial intelligence while preserving patient privacy and institutional governance through decentralized computational training.[24]

Participating healthcare institutions independently train local foundation AI models using radiological imaging, digital pathology, genomic sequencing, laboratory investigations, wearable monitoring, and longitudinal clinical records while securely exchanging encrypted model parameters rather than identifiable patient information. This collaborative learning strategy substantially improves algorithm robustness, fairness, external validity, and generalizability across diverse healthcare environments.

Federated cross-modal intelligence therefore establishes an international computational oncology network capable of accelerating scientific discovery, improving equitable access to precision medicine, and supporting global cancer research while maintaining responsible data stewardship.

14. Explainability, Validation, and Ethical Governance

Successful implementation of cross-modal artificial intelligence requires transparent, interpretable, reproducible, and rigorously validated computational systems capable of supporting clinician confidence, patient trust, and regulatory approval. Explainable artificial intelligence (XAI) enables clinicians to understand computational reasoning through attention visualization, saliency maps, SHAP (Shapley Additive Explanations), feature attribution analysis, uncertainty estimation, and counterfactual explanations identifying the imaging, molecular, pathological, physiological, and clinical variables responsible for predictive outputs.[25]

Clinical deployment additionally requires standardized multimodal datasets, interoperable computational infrastructure, prospective multicenter validation, external benchmarking, cybersecurity safeguards, continuous monitoring for algorithmic bias, and compliance with evolving international regulatory frameworks governing AI-enabled healthcare technologies.

Responsible implementation further depends upon protection of patient privacy, informed consent, transparency, accountability, equitable access, responsible data governance, and continuous post-deployment surveillance to ensure trustworthy integration of cross-modal AI systems into routine oncology practice.

15. Future Perspectives

Future cross-modal artificial intelligence ecosystems will increasingly integrate multimodal

Paper Available at: www.ijarai.com
DOI : https://doi.org/10.65713/ijaraiv14i1202

foundation models, multimodal large language models, agentic artificial intelligence, graph neural networks, reinforcement learning, federated learning, digital twins, spatial multi-omics, liquid biopsy, quantum computing, Internet of Medical Things (IoMT) technologies, robotics, cloud-native healthcare infrastructure, and autonomous clinical reasoning systems into unified precision oncology platforms.[26]

These next-generation computational ecosystems will continuously integrate molecular biology, imaging, pathology, laboratory medicine, wearable physiological monitoring, environmental exposures, electronic health records, biomedical literature, and real-world clinical outcomes while autonomously coordinating diagnostic workflows, optimizing therapeutic strategies, supporting adaptive clinical trials, generating personalized patient communication, and continuously synthesizing biomedical evidence.

Such intelligent ecosystems are expected to transform oncology from fragmented and reactive disease management toward predictive, preventive, adaptive, continuously learning, and precision-guided healthcare across the global cancer community.

16. Discussion

Cross-modal artificial intelligence represents one of the most significant paradigm shifts in computational oncology by integrating radiology, histopathology, genomics, laboratory medicine, and longitudinal clinical intelligence into unified computational ecosystems capable of supporting comprehensive personalized cancer care. Unlike conventional artificial intelligence systems developed for isolated predictive tasks, these intelligent frameworks simultaneously analyze molecular biology, tissue architecture, imaging phenotypes, physiological monitoring, environmental influences, and clinical trajectories to generate holistic representations of cancer biology.[27]

Applications spanning computational pathology, radiogenomics, biomarker discovery, digital twins, precision immunotherapy, adaptive therapeutics, continuous learning, federated collaboration, digital health, survivorship management, and intelligent clinical decision support demonstrate the extraordinary potential of cross-modal artificial intelligence to redefine future oncology. Nevertheless, successful implementation requires continued advances in multimodal data harmonization, explainable artificial intelligence, interoperability, computational infrastructure, cybersecurity, regulatory science, ethical governance, and sustained multidisciplinary collaboration.

As biomedical knowledge and healthcare data continue to expand exponentially, cross-modal artificial intelligence is expected to become the central computational infrastructure supporting intelligent precision oncology worldwide.

17. Conclusion

Cross-modal artificial intelligence is transforming precision oncology by integrating radiology, histopathology, genomics, laboratory biomarkers, wearable technologies, electronic health records, digital twins, and longitudinal clinical intelligence into unified computational ecosystems capable of supporting accurate diagnosis, biomarker discovery, prognostic prediction, therapeutic optimization, adaptive disease monitoring, and personalized cancer care throughout the disease continuum.[28]

Advances in transformer architectures, multimodal learning, graph neural networks, self-supervised learning, federated learning, reinforcement learning, digital twins, multimodal large language models, agentic AI, and generative artificial intelligence are expected to further strengthen these intelligent ecosystems, enabling increasingly accurate molecular characterization, predictive clinical decision-making, adaptive therapeutics, continuous disease surveillance, and personalized oncology care.[29]

Although important scientific, technical, ethical, regulatory, and implementation challenges remain, sustained collaboration among oncologists, radiologists, pathologists, molecular biologists, biomedical engineers, computer scientists, healthcare organizations, policymakers, industry partners, and regulatory agencies will accelerate the responsible implementation of cross-modal artificial intelligence. These innovations have the potential to improve patient outcomes, enhance healthcare efficiency, reduce

Paper Available at: www.ijarai.com
DOI : https://doi.org/10.65713/ijaraiv14i1202

Volume 14, Issue-12
December, 2024, P02
ISSN: 2319-9253

disparities in cancer care, accelerate translational research, and establish a new era of intelligent, adaptive, and continuously learning precision oncology worldwide.[30]

References

1. Meric-Bernstam, F. et al. (2023) ‘Enhancing Precision Oncology Through Multimodal Data Integration’, Nature Reviews Clinical Oncology, 20(4), pp. 267-283.
2. Chaudhary, K. et al. (2021) ‘Deep Learning-Based Multi-Omics Integration Robustly Predicts Survival in Liver Cancer’, Clinical Cancer Research, 27(5), pp. 1248-1259.
3. Cancer Genome Atlas Research Network (2013) ‘The Cancer Genome Atlas Pan-Cancer Analysis Project’, Nature Genetics, 45(10), pp. 1113-1120.
4. Huang, S.C. et al. (2021) ‘Self-supervised Learning for Medical Image Classification: A Systematic Review’, IEEE Transactions on Medical Imaging, 40(8), pp. 2021-2037.
5. Moor, M. et al. (2023) ‘Foundation Models for Generalist Medical Artificial Intelligence’, Nature, 616(7956), pp. 259-265.
6. Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12(1):31–46. Doi:10.1158/2159-8290.CD-21-1059.
7. Singhal K, Azizi S, Tu T, et al. Large language models encode clinical knowledge. Nature. 2023;620(7972):172–180. Doi:10.1038/s41586-023-06291-2.
8. Xu H, Usuyama N, Bagga J, et al. A whole-slide foundation model for digital pathology from real-world data. Nature. 2024;630(8015):181–188. Doi:10.1038/s41586-024-07441-w.
9. Moor M, Banerjee O, Abad ZSH, et al. Foundation models for generalist medical artificial intelligence. Nature. 2023;616(7956):259–265. Doi:10.1038/s41586-023-05881
10. 10. 30. Bommasani R, Hudson DA, Adeli E, et al. On the opportunities and risks of foundation models. arXiv. 2021. Doi:10.48550/arXiv.2108.07258.
11. Dosovitskiy A, Beyer L, Kolesnikov A, et al. An image is worth 16×16 words: transformers for image recognition at scale. arXiv. 2020. Doi:10.48550/arXiv.2010.11929.
12. Dr. Ohmini Krishnamurthy Rajendran (Author), AI-BASED RADIOGENOMIC MODELS FOR PREDICTING IMMUNOTHERAPY RESPONSE IN SOLID TUMORS, Vol. 51 No. 4 (2023): October-December 2023, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/321 , DOI: https://doi.org/10.46121/pspc.51.4.4
13. Dr. Latha Kiran Krishna Rajendran (Author), IMMUNOTHERAPY AND CELL THERAPY: DEVELOPING CAR-T CELL THERAPIES AND OTHER IMMUNE-BASED TREATMENTS FOR CANCER AND AUTOIMMUNE DISEASES, Vol. 51 No. 2 (2023): April-June 2023, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/304 , DOI: https://doi.org/10.46121/pspc.51.2.7
14. Chakraborty, S. et al. (2022) ‘Multi-omics Integration in Oncology: From Data to Clinical Insights’, Cancer Cell, 40(8), pp. 805-823.
15. Dr. Ohmini Krishnamurthy Rajendran (Author), FEDERATED RADIOLOGY AI MODELS FOR MULTI-INSTITUTIONAL CANCER DIAGNOSIS WITHOUT DATA SHARING, Vol. 51 No. 4 (2023): October-December 2023, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/323 , DOI: https://doi.org/10.46121/pspc.51.4.5
16. Dr. Latha Kiran Krishna Rajendran (Author), MECHANISMS DRIVING IMMUNOTHERAPY RESISTANCE IN COLORECTAL CANCER LIVER METASTASES, Vol. 52 No. 1 (2024): January-March 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/303 , DOI: https://doi.org/10.46121/pspc.52.1.5
17. Dr. Ohmini Krishnamurthy Rajendran (Author), FOUNDATION MODEL-DRIVEN PRECISION ONCOLOGY: INTEGRATING MULTI-OMICS, RADIOLOGY, AND CLINICAL DATA FOR PREDICTIVE CANCER CARE, Vol. 52 No. 2 (2024): April-June 2024, Power System Protection and Control, ISSN-1674-3415,

https://pspac.info/index.php/dlbh/article/view/324 , DOI: https://doi.org/10.46121/pspc.52.2.14

18. Dr. Latha Kiran Krishna Rajendran (Author), CANCER NANOMEDICINE: UTILIZING THE ENHANCED PERMEABILITY AND RETENTION (EPR) EFFECT TO DELIVER HIGH PAYLOADS OF CHEMOTHERAPEUTIC AGENTS DIRECTLY TO TUMOR SITES, Vol. 52 No. 2 (2024): April-June 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/311, DOI: https://doi.org/10.46121/pspc.52.2.12
19. Dr. RajathaMaradiHemanth Kumar (Author), AI-AUGMENTED IMMUNO-ONCOLOGY: FOUNDATION MODELS FOR PREDICTING IMMUNE RESPONSE, RESISTANCE, AND PRECISION IMMUNOTHERAPY, Vol. 52 No. 2 (2024): April–June 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/345 , DOI: https://doi.org/10.46121/pspc.52.2.18
20. Dr. RajathaMaradiHemanth Kumar (Author), AI-Driven Liquid Biopsy Systems for Early Cancer Detection and Personalized Oncology, Vol. 51 No. 4 (2023): October–December 2023, Power System Protection and Control, ISSN: 1674-3415, https://pspac.info/index.php/dlbh/article/view/388 , DOI: https://doi.org/10.46121/pspc.51.4.7
21. Dr. Ohmini Krishnamurthy Rajendran (Author), SELF-SUPERVISED MULTIMODAL LEARNING FOR EARLY CANCER DETECTION ACROSS IMAGING AND GENOMICS, Vol. 52 No. 4 (2024): October-December 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/325, DOI: https://doi.org/10.46121/pspc.52.4.14
22. Dr. RajathaMaradiHemanth Kumar (Author), MULTIMODAL FOUNDATION AI MODELS IN PRECISION ONCOLOGY: INTEGRATING RADIOMICS, PATHOMICS, MULTI-OMICS, AND CLINICAL INTELLIGENCE SYSTEMS, Vol. 52 No. 4 (2024): October–December 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/343 , DOI: https://doi.org/10.46121/pspc.52.4.16
23. Joshi, A. et al. (2023) ‘Multimodal Learning for Precision Oncology: Beyond Single-modality Analysis’, npj Precision Oncology, 7(1), p. 28.
24. Dr. Latha Kiran Krishna Rajendran (Author), Genomic Profiling: Utilizing Multi-Omics Data to Identify Potential Therapeutic Targets and Resistance Markers, Vol. 52 No. 4 (2024): October–December 2024, Power System Protection and Control, ISSN: 1674-3415, Article URL: https://pspac.info/index.php/dlbh/article/view/312 , DOI: https://doi.org/10.46121/pspc.52.4.13.
25. Huang, S.C. et al. (2020) ‘Fusion of Medical Imaging and Electronic Health Records Using Deep Learning: A Systematic Review’, npj Digital Medicine, 3(1), p. 136.
26. Dr. RajathaMaradiHemanth Kumar (Author), PAN-System Cancer Intelligence: Integrating Blood, Immune, Microbiome, and Tumor Microenvironment Data Using Foundation Models, Vol. 51 No. 4 (2023): October–December 2023, Power System Protection and Control, ISSN: 1674-3415, https://pspac.info/index.php/dlbh/article/view/389, DOI: https://doi.org/10.46121/pspc.51.4.8
27. Lambin, P. et al. (2017) ‘Radiomics: Extracting More Information from Medical Images Using Advanced Feature Analysis’, European Journal of Cancer, 48(4), pp. 441-446.
28. Zwanenburg, A. et al. (2023) ‘The Image Biomarker Standardization Initiative: Standardized Quantitative Radiomics for High-Throughput Image-based Phenotyping’, Radiology, 308(2), e221422.
29. Chen, R.J. et al. (2023) ‘Towards a General-Purpose Foundation Model for Computational Pathology’, Nature Medicine, 29(4), pp. 850-862.
30. Kather, J.N. et al. (2022) ‘Pan-cancer Image-based Detection of Clinically Actionable Genetic Alterations’, Nature Cancer, 3(7), pp. 789-799.